Related Experiment Video

Updated: Jun 10, 2026

3D Whole-heart Myocardial Tissue Analysis
06:53

3D Whole-heart Myocardial Tissue Analysis

Published on: April 12, 2017

Biomarker-guided treatment of congestive heart failure

Yang Xue1, Jeffrey Chan, Sonal Sakariya

  • 1University of California San Diego UCSD Medical Center, San Diego, CA 92103-8411, USA. yaxue@ucsd.edu

Congestive Heart Failure (Greenwich, Conn.)
|July 27, 2010
PubMed

Insights

Biomarker-guided heart failure therapy, using natriuretic peptides, shows promising results. This approach is non-inferior and sometimes superior to standard care, aiding heart failure management.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Public Health

Background:

  • Heart failure management is a growing public health concern with challenges in therapy development and implementation.
  • Natriuretic peptides serve as cost-effective and reliable biomarkers for monitoring treatment response in heart failure.
  • There is increasing interest in utilizing objective and accessible biomarkers to guide heart failure therapy.

Purpose of the Study:

  • To evaluate the effectiveness of biomarker-guided heart failure therapy compared to standard medical management.
  • To assess the role of natriuretic peptides in optimizing heart failure treatment strategies.
  • To explore the integration of biomarkers into routine heart failure care.

Main Methods:

  • Review of several clinical trials investigating natriuretic peptide-guided heart failure therapy.
  • Comparison of outcomes between biomarker-guided therapy and intensive medical management.
  • Analysis of biomarker objectivity, reproducibility, and accessibility in clinical practice.

Main Results:

  • Biomarker-guided heart failure therapy demonstrated non-inferiority to intensive medical management overall.
  • Specific patient populations showed slight superiority with natriuretic peptide-guided therapy.
  • Trials like the New Zealand study and others yielded very promising results.

Conclusions:

  • Biomarker-guided heart failure therapy is effective and shows potential for routine clinical integration.
  • Further large-scale trials are needed to validate these promising findings.
  • Natriuretic peptide-guided therapy offers a valuable approach to enhance heart failure management.

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...